Sugi Predict

Sugi Predict / Compounds / SCHEMBL4426191

SCHEMBL4426191

SCHEMBL4426191

CCP(=O)(Oc1ccccc1Cl)Oc1ccccc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ LMNA P02545 1/20 0.58
▸ POLB P06746 2/20 0.44
▸ PKM P14618 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ L3MBTL1 Q9Y468 4/20 0.43
▸ HPGD P15428 3/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ PTK2B Q14289 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233559 0.84 PKM (0.49) SMN1; SMN2LMNAPKML3MBTL1MEN1
SCHEMBL778576 0.82 L3MBTL1 (0.47) SMN1; SMN2LMNAL3MBTL1HPGDTSHR
SCHEMBL4422355 0.82 LMNA (0.51) SMN1; SMN2LMNAPOLBPKMGAA
SCHEMBL4426186 0.80 LMNA (0.49) SMN1; SMN2LMNAPKM
SCHEMBL777121 0.78 KDM4E (0.45) SMN1; SMN2LMNAPOLBL3MBTL1TSHR
SCHEMBL3225021 0.78 LMNA (0.55) SMN1; SMN2LMNAPOLBPKMGAA
SCHEMBL28032322 0.78 LMNA (0.64) SMN1; SMN2LMNAPOLBPKMGAA
SCHEMBL2035293 0.77 LMNA (0.69) SMN1; SMN2LMNAPOLBPKMGAA
SCHEMBL18632008 0.77 HTT (0.53) SMN1; SMN2LMNAPOLBGAAL3MBTL1
SCHEMBL14216107 0.76 LMNA (0.45) SMN1; SMN2LMNAPOLBPKMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015372-A1 Organophosphorous Compounds and Uses Thereof JAL THERAPEUTICS LLC (US) 2026-01-15 — — US claimed
WO-2024020507-A2 ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF JAL THERAPEUTICS, LLC (US) 2024-01-25 — — WO claimed
US-20260015372-A1 Organophosphorous Compounds and Uses Thereof JAL THERAPEUTICS LLC (US) 2026-01-15 — — US disclosed
WO-2024020507-A2 ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF JAL THERAPEUTICS, LLC (US) 2024-01-25 — — WO disclosed
WO-2024020507-A2 ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF JAL THERAPEUTICS, LLC (US) 2024-01-25 — — WO disclosed
US-20180104263-A1 BUTYRYLCHOLINESTERASE INHIBITORS JAL THERAPEUTICS, LLC 2018-04-19 — — US disclosed
US-20180104263-A1 BUTYRYLCHOLINESTERASE INHIBITORS JAL THERAPEUTICS, LLC 2018-04-19 — — US disclosed
US-20180104263-A1 BUTYRYLCHOLINESTERASE INHIBITORS JAL THERAPEUTICS, LLC 2018-04-19 — — US disclosed
EP-2097428-B1 BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MGP BIOTECHNOLOGIES INC (US) 2018-02-28 — — EP disclosed
EP-2097428-B1 BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MGP BIOTECHNOLOGIES INC (US) 2018-02-28 — — EP disclosed
US-9757399-B2 Butyrylcholinesterase inhibitors JAL THERAPEUTICS, INC. (US) 2017-09-12 — — US disclosed
US-20160206635-A1 Butyrylcholinesterase Inhibitors JAL THERAPEUTICS, LLC 2016-07-21 — — US disclosed
US-20160206635-A1 Butyrylcholinesterase Inhibitors JAL THERAPEUTICS, LLC 2016-07-21 — — US disclosed
US-20140073608-A1 Butyrylcholinesterase Inhibitors MGP BIOTECHNOLOGIES, LLC (US) 2014-03-13 — — US disclosed
US-20140073608-A1 Butyrylcholinesterase Inhibitors MGP BIOTECHNOLOGIES, LLC (US) 2014-03-13 — — US disclosed
US-20100069337-A1 BUTYRYLCHOLINESTERASE INHIBITORS JAL THERAPEUTICS, LLC 2010-03-18 — — US disclosed
US-20100069337-A1 BUTYRYLCHOLINESTERASE INHIBITORS JAL THERAPEUTICS, LLC 2010-03-18 — — US disclosed
EP-2097428-A2 BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Mgp Biotechnologies, Inc. (US) 2009-09-09 — — EP disclosed
WO-2008055249-A2 BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MGP BIOTECHNOLOGIES, INC. (US) 2008-05-08 — — WO disclosed
WO-2008055249-A2 BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MGP BIOTECHNOLOGIES, INC. (US) 2008-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180104263-A1 BUTYRYLCHOLINESTERASE INHIBITORS BCHE, ACHE, PSEN1 SMN1; SMN2 178/4885LMNA 1641/4885POLB 617/4885
US-20160206635-A1 Butyrylcholinesterase Inhibitors BCHE, ACHE, PSEN1 SMN1; SMN2 178/4885LMNA 1641/4885POLB 617/4885
US-20140073608-A1 Butyrylcholinesterase Inhibitors BCHE, ACHE, PSEN1 SMN1; SMN2 178/4885LMNA 1641/4885POLB 617/4885
US-20100069337-A1 BUTYRYLCHOLINESTERASE INHIBITORS BCHE, ACHE, PSEN1 SMN1; SMN2 178/4885LMNA 1641/4885POLB 617/4885
US-20260015372-A1 Organophosphorous Compounds and Uses Thereof ACHE, BCHE, MUSK SMN1; SMN2 415/4885LMNA 2268/4885POLB 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.